Loncar Cancer Immunotherapy ETF (CNCR): Price and Financial Metrics ETF
GET POWR RATINGS... FREE!
CNCR Stock Price Chart Interactive Chart >
CNCR Price/Volume Stats - 7 Best ETFs for the NEXT Bull Market
Current price | $14.65 | 52-week high | $19.76 |
Prev. close | $14.92 | 52-week low | $12.76 |
Day low | $14.65 | Volume | 100 |
Day high | $14.87 | Avg. volume | 2,526 |
50-day MA | $14.43 | Dividend yield | 0.00001% |
200-day MA | $15.16 |
Loncar Cancer Immunotherapy ETF (CNCR) ETF Bio
The investment objective of the Loncar Cancer Immunotherapy ETF seeks to replicate the Loncar Cancer Immunotherapy Index. The index was developed by a top biologist and includes large pharmaceutical and growth-oriented biotechnology firms that are focused on improving cancer treatments.
CNCR ETF Info
Issuer | Exchange Traded Concepts |
Expense Ratio | 0.79% |
Underlying Index | Loncar Cancer Immunotherapy Index |
Asset Class | Equity |
Sector | Health & Biotech ETFs |
Assets Under Management (AUM) | 21.98M |
Net Asset Value (NAV) | $14.65 |
Options? | Yes |
Total Holdings | 31 |
CNCR Top Holdings
Symbol | Company | % of Total |
JANX | Janux Therapeutics Inc | 0.06% |
RAPT | Rapt Therapeutics Inc | 0.05% |
BGNE | BEIGENE LTD | 0.04% |
IOVA | Iovance Biotherapeutics Inc | 0.04% |
IGMS | IGM Biosciences Inc | 0.04% |
XNCR | Xencor Inc | 0.04% |
MRUS | Merus NV | 0.04% |
ALLO | Allogene Therapeutics | 0.04% |
CRSP | CRISPR Therapeutics AG | 0.04% |
CNCR Price Returns
1-mo | 6.70% |
3-mo | -0.68% |
6-mo | -12.85% |
1-year | -24.42% |
3-year | -24.55% |
5-year | -43.24% |
YTD | 6.70% |
2022 | -42.31% |
2021 | -19.24% |
2020 | 36.53% |
2019 | 24.22% |
2018 | -20.65% |
CNCR Dividends
Ex-Dividend Date | Type | Payout Amount | Change | ||||||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |